Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
There are few randomized clinical trials in advanced HIV patients. This is a multicenter,
randomized, open clinical trial, comparing three parallel groups, to compare the
immunological reconstitution and the virological efficacy and safety of three different
combinations of antiretroviral therapy given once a day (QD): tenofovir plus emtricitabine
plus either efavirenz, lopinavir-ritonavir or atazanavir-ritonavir during 96 weeks in
advanced antiretroviral naïve HIV-1 infected patients with less than 100 CD4+ T-cells/mm3.
Primary endpoint is the median increase in CD4+ T-cell count at 48 weeks after starting
HAART.